NCT00191750

A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned

Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (planned)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purposes of this study are to determine 1) the safety of pemetrexed and any side effects that might be associated with it 2) whether pemetrexed can help patients with small cell lung cancer live longer 3) whether pemetrexed can make tumors smaller or disappear and for how long and 4) to see if patients feel better while taking pemetrexed

Conditions

• Carcinoma, Small Cell

Interventions

Type	Name	Description
DRUG	Pemetrexed

Timeline

• Start date: 2004-07-01
• Completion: 2006-09-01
• First posted: 2005-09-19
• Last updated: 2007-01-26

Locations

3 sites across 1 country: United States